Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy

被引:4
作者
Novotny, Alexander R. [1 ]
Reim, Daniel [1 ]
Friess, Helmut M. [1 ]
Schuhmacher, Christoph [1 ]
机构
[1] Tech Univ Munich, Dept Surg, Klinikum Rechts Isar, D-81675 Munich, Germany
关键词
Gastric cancer; Stomach cancer; Metastatic; Chemotherapy; Surgery; Survival; ADVANCED ESOPHAGOGASTRIC CANCER; GASTRIC-CANCER; PERIOPERATIVE CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; PALLIATIVE RESECTION; SURGERY; CARCINOMA; CLASSIFICATION; CAPECITABINE; OXALIPLATIN;
D O I
10.1007/s00423-014-1217-3
中图分类号
R61 [外科手术学];
学科分类号
摘要
With improved chemotherapeutic regimens, metastasized gastric cancer may show a good response rendering an initially unresectable tumor resectable. We performed a retrospective analysis on the outcome of stage IV gastric cancer patients treated by chemotherapy followed by oncologic resection in a western institution. From August 1988 to December 2010, a total number of 1,817 patients underwent surgery for gastric cancer at the Department of Surgery, Technical University of Munich. A retrospective analysis of our prospective gastric cancer database identified 58 patients with stage IV gastric cancer having undergone induction chemotherapy followed by surgery in an individualized treatment concept. After induction chemotherapy usually consisting of 2 cycles of PLF (cisplatin, 5-fluorouracil, leucovorin), resection was performed with or without removal of metastases in patients without disease progression. Patients were followed up until death or loss to follow up. The three most common metastatic locations were liver (27.6 %), distant lymph nodes (22.4 %), and peritoneum (19.0 %). Of patients, 13.8 % had metastases in more than one location. Thirty-day mortality was 5.2 %, 90-day mortality was 13.8 %, while overall postoperative morbidity accounted for 24 %. In 19 (32.8 %) patients, a complete resection without any macroscopic tumor residues was achieved. In 39 (67.2 %) patients, tumors could not be completely removed with either local residual disease or residual disease at distant sites. Overall median survival was 20 months, while patients without residual tumor survived significantly longer (72 months) than patients with residual disease (12 months, p = 0.001). Secondary surgery of metastasized gastric cancer may be justified in selected cases without progression under induction chemotherapy. An achievable complete removal of the primary tumor and metastases appears the main selection criterion for patients benefitting from this approach.
引用
收藏
页码:773 / 781
页数:9
相关论文
共 30 条
[1]   Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy [J].
Becker, K ;
Mueller, JD ;
Schulmacher, C ;
Ott, K ;
Fink, U ;
Busch, R ;
Böttcher, K ;
Siewert, JR ;
Höfler, H .
CANCER, 2003, 98 (07) :1521-1530
[2]  
Boige V, 2007, J CLIN ONCOL, V25
[3]  
BOZZETTI F, 1987, SURG GYNECOL OBSTET, V164, P151
[4]   The Value of Palliative Gastrectomy in Gastric Cancer with Distant Metastasis [J].
Chang, Ye Rim ;
Han, Dong Seok ;
Kong, Seong-Ho ;
Lee, Hyuk-Joon ;
Kim, Se Hyung ;
Kim, Woo Ho ;
Yang, Han-Kwang .
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (04) :1231-1239
[5]   Quality of life in patients with oesophageal and gastric cancer: An overview [J].
Conroy, Thierry ;
Marchal, Frederic ;
Blazeby, Jane M. .
ONCOLOGY, 2006, 70 (06) :391-402
[6]   Capecitabine and oxaliplatin for advanced esophagogastric cancer [J].
Cunningham, David ;
Starling, Naureen ;
Rao, Sheela ;
Iveson, Timothy ;
Nicolson, Marianne ;
Coxon, Fareeda ;
Middleton, Gary ;
Daniel, Francis ;
Oates, Jacqueline ;
Norman, Andrew Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :36-46
[7]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[8]   Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. [J].
Cunningham, David ;
Okines, Alicia F. C. ;
Ashley, Sue .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (09) :858-859
[9]   Classification of surgical complications - A new proposal with evaluation in a cohort of 6336 patients and results of a survey [J].
Dindo, D ;
Demartines, N ;
Clavien, PA .
ANNALS OF SURGERY, 2004, 240 (02) :205-213
[10]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247